What Is Semaglutide? GLP-1 Weight Loss Medications Explained in Plain English

Bottom line: Semaglutide and tirzepatide are GLP-1 receptor agonists that produce 15–21% average body weight loss in clinical trials — 3–5x the outcome of diet programs. Compounded versions are available through telehealth at $179–$225/month, requiring physician assessment for eligibility. They work by restoring hormonal satiety signals, not by requiring willpower.

---

In the past five years, GLP-1 receptor agonists have fundamentally changed what clinical medicine thinks is achievable in weight management. The clinical trial data is not incremental. It represents a category shift.

Here’s what these medications are, how they work, and what the evidence actually shows.

GLP-1: The Hormone Behind the Medication

GLP-1 (glucagon-like peptide-1) is a hormone produced by cells in your small intestine after you eat. Its job is to signal your body that food has arrived:

• It signals your pancreas to release insulin in response to glucose
• It signals your brain’s appetite centers that you’ve eaten — reducing hunger
• It slows gastric emptying — food leaves your stomach more slowly, extending the feeling of fullness
• It reduces the brain’s hedonic (pleasure-driven) drive to seek out high-calorie food

People with obesity often have disrupted GLP-1 signaling. The “I’m full” signal arrives late or weakly, contributing to overconsumption that isn’t driven by lack of willpower but by dysregulated hormonal feedback.

GLP-1 receptor agonists are synthetic molecules that bind to the same receptors and activate the same pathways — but with much longer duration than the hormone your body produces naturally. Where natural GLP-1 lasts minutes, weekly semaglutide injections maintain receptor activation for seven days.

The Four GLP-1 Medications You’ll Hear About

Semaglutide:

• Ozempic (0.5–2mg weekly injection) — FDA-approved for type 2 diabetes
• Wegovy (2.4mg weekly injection) — FDA-approved for weight management
• Rybelsus (oral tablet, lower bioavailability, less commonly used for weight loss)
• Compounded semaglutide — same active ingredient, $179–$225/month through telehealth

Tirzepatide:

• Mounjaro — FDA-approved for type 2 diabetes
• Zepbound — FDA-approved for weight management
• Compounded tirzepatide — available through some telehealth platforms
• GIP + GLP-1 dual agonist — activates two receptor types, explains superior efficacy

Tirzepatide’s dual mechanism produces higher average weight loss than semaglutide alone (20.9% vs. 15.7% in pivotal trials). Some patients respond better to one or the other — physician assessment determines the appropriate starting point.

What to Expect: The First 12 Months

Weeks 1–4: Dose titration begins at a low dose to minimize side effects. Most patients experience mild nausea, especially in the first 2–3 weeks. Appetite reduction is noticeable within the first week for most patients.

Weeks 4–12: Dose increases through a standard titration schedule. Gastrointestinal side effects typically resolve as the body adjusts. Weight loss of 3–7% is typical in this window.

Months 3–6: The dose approaches therapeutic levels. Appetite suppression is consistent. Most patients in clinical trials see meaningful weight loss (7–12% body weight) by month 6.

Months 6–12: Continued weight loss approaching the plateau phase. Clinical trials measure peak efficacy at 12 months: 15–21% average body weight loss in pivotal trials.

Ongoing: Weight is regained after discontinuation in most patients — these medications treat obesity as a chronic condition, similar to how blood pressure medications treat hypertension. Long-term use is the expected model for patients with sustained weight management needs.

What is semaglutide and how does it cause weight loss?

Semaglutide is the active ingredient in Ozempic and Wegovy. It mimics GLP-1, a hormone your gut produces after eating, signaling satiety to the brain and slowing gastric emptying so you feel full longer. Clinical trials show 14.9% average body weight loss at 68 weeks (NEJM STEP 1, 2021). Compounded versions are available through telehealth at $179–$225/month.

The Compounded Option: What Changed the Access Equation

Wegovy launched at $1,349/month list price. Mounjaro at $1,023/month. Without insurance coverage for weight management — which most plans still exclude — these prices put GLP-1 medications out of reach for most patients.

Compounded semaglutide and tirzepatide, available through telehealth platforms like Gala, TrimRX, and Viviomd, use the same active ingredients at $179–$225/month. They are not identical to brand-name products (excipients may differ) and are not FDA-approved branded drugs. But they are legally compounded, physician-prescribed, and dispensed from accredited US pharmacies.

Our GLP-1 program comparison covers eligibility requirements, pricing structures, and clinical oversight across the three leading telehealth platforms — including which programs accept BMI 27+ with a qualifying condition. For the biology behind why GLP-1 medications work when calorie restriction consistently fails, see why every diet fails and what GLP-1 does differently. For a full annual cost breakdown — brand name vs compounded vs diet programs, with per-pound-lost math — see The Honest Math on GLP-1 Alternatives in 2026.